CyteVice

Alvin Dabhi

Aditya Sai

5/1/2013

“Discover the discovery”

The Opportunity Fatty liver diseases have been linked to diabetes and obesity; affect

6 million people in the US and approximately 10-20% of Americans have significant liver fat content

Global drug discovery market was $41.4 billion in 2012, with high throughput screening comprising approximately 30% of the market; this equates to a $1.3 billion market segment to be tapped within the fatty liver drug market

A potential drug costs between $55 million to $1.3 billion to bring to market; contracting the drug discovery phase will save time and money for companies

Discovery

(5 years)

Preclinical

(2 years)

Clinical

(6 years)Marketing

Drug Development Process

The Product CyteVice is a diagnostic tool

capable of screening for the best agents to defat candidate livers

Specially coated 96 well plate assays that can be fitted for manual or automated use

Prepackaged cells sustained within device to allow for more targeted testing

>85% cell viability maintained Proprietary content: Patent

Pending

Market Description

Pharmaceuticals Key customers in the liver defatting market Potential Market Size: $125 million

Academic Research labs Select researchers may find product desirable Potential Market Size: $50 million

Potential growth opportunities available in other diseases that can be screened and treated in similar manner (obesity, Hepatitis C, etc.)

Competitive EdgeCyteVice Competitors (ForteBIO,

EVOTec)

Direct Application to Liver Disease

Specifically targeted Not targeted to specific disease

Usage of Cells Specialized cells within each plate with necessary reagents

None

Cell Viability Above Average Average

Precision >99% reproducible results Closest competitor has ~85% precision

Shelf Life 6 months 2-3 months

“Viability Assurance” Included with every device None

Business Model

Offer screening devices to our customers Product Selling Points

Preset cells, reagents “Viability Assurance”

Negotiate volume contracts with key resource providers, such as Life Technologies® and BD Biosciences®, at lowest possible cost

Our Team

Key Members: CEO: Carlton Jones

3 decades of experience in developing innovative instrumentation and consumables

CFO: Wendy DiCicco Long history as finance chief in biotechnology and medical device

startups COO: Shannon Dahl, Ph.D.

Operations officer in tissue engineering company Principal Board Advisor: Dr. Francois Berthiaume, Ph.D.

Well versed in liver defatting methodologies and hepatocyte models

Investment Request 2 infusions of $1,000,000 and

$200,000 respectively $10.5 million exit value at year 6 Investments will go into:

hiring of technicians and scientists: $500,000 procurement of starting materials: $150,000 capital & property expenditures: $150,000 pilot production: $150,000 marketing, press releases, webinars,

conference events, sales representatives: $250,000

Financial Summary

Year 1 Year 2 Year 30

500

1,000

1,500

2,000

2,500

3,000

3,500

Projected Revenues and Incomes for 3 Years After Launch

Projected Net Revenue

Projected Net Income

Do

llar

s (

Th

ou

san

ds

of

$s)

Projected Cost Per Device:

$80Projected

Retail Price Per Device:

$250

Projected Net

Present Value:

$2,046,000

Product Timeline•Secure first infusion of $1,000,000•Design coating protocol & hire technicians•Procurement of resources from suppliersYear 1•Construct pilot plant•Finalize coating protocol & hire scientists•Publicize product in research papers, webinars, etc. 2•Pilot production•Secure second infusion of $200,000•Begin selling purchase orders to customers3•Aggressive direct marketing to potential customers •Research alternative cell and capacity models4•Begin production of alternate products & expand pipeline5

Summary and Q&A

CyteVice has an important role in the drug discovery market within the area of fatty liver disease No established screening tool used in testing Addresses vital need in drug discovery Specialized platform to conduct high throughput cell based

assays Selling prepackaged cells along with assays Expansion to incorporate other tissue types and therapeutics

Ambitious startup with experienced advisors seeking investment for a transformative product to revolutionize drug screening